stockportfolio.pro
Stocks / JNJ vs LLY
JNJ vs LLY
Johnson & Johnson and Eli Lilly and Company side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Johnson & Johnson (JNJ) | Eli Lilly and Company (LLY) | |
|---|---|---|
| Market cap | $570.5B | $1.02T |
| Revenue (latest FY) | $94.19B | $65.18B |
| Net income (latest FY) | $26.80B | $20.64B |
| Revenue growth (5y CAGR) | 2.7% | 21.6% |
| Net margin | 28.5% | 31.7% |
| Return on equity | 32.9% | 77.8% |
| P/E ratio | 26.9 | 40.7 |
| Dividend yield | 2.3% | 0.6% |
| Profitable years (of last 10) | 10 | 9 |
| Positive free cash flow | Yes | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open JNJ — free Open LLY — freeFrequently asked questions
Which is bigger, JNJ or LLY?
Eli Lilly and Company is larger by market capitalization — $1.02T versus $570.5B.
Which grows faster, JNJ or LLY?
Over the last five fiscal years, Eli Lilly and Company grew revenue faster — 21.6%/yr versus 2.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.